Projected life expectancy of people with HIV according to timing of diagnosis
Top Cited Papers
- 28 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 26 (3), 335-343
- https://doi.org/10.1097/qad.0b013e32834dcec9
Abstract
Background and objectives: Effective antiretroviral therapy (ART) has contributed greatly toward survival for people with HIV, yet many remain undiagnosed until very late. Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy. Methods: A stochastic computer simulation model of HIV infection and the effect of ART was used to estimate life expectancy and determine the distribution of potential lifetime outcomes of an MSM, aged 30 years, who becomes HIV positive in 2010. The effect of altering the diagnosis rate was investigated. Results: Assuming a high rate of HIV diagnosis (median CD4 cell count at diagnosis, 432 cells/μl), projected median age at death (life expectancy) was 75.0 years. This implies 7.0 years of life were lost on average due to HIV. Cumulative risks of death by 5 and 10 years after infection were 2.3 and 5.2%, respectively. The 95% uncertainty bound for life expectancy was (68.0,77.3) years. When a low diagnosis rate was assumed (diagnosis only when symptomatic, median CD4 cell count 140 cells/μl), life expectancy was 71.5 years, implying an average 10.5 years of life lost due to HIV. Conclusion: If low rates of virologic failure observed in treated patients continue, predicted life expectancy is relatively high in people with HIV who can access a wide range of antiretrovirals. The greatest risk of excess mortality is due to delays in HIV diagnosis.Keywords
This publication has 46 references indexed in Scilit:
- Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational studyThe Lancet, 2010
- Long-term trends in adherence to antiretroviral therapy from start of HAARTAIDS, 2010
- Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance DetectionClinical Infectious Diseases, 2010
- Cardiovascular Risk Assessment in Antiretroviral-Naïve HIV PatientsAIDS Patient Care and STDs, 2009
- The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over TimeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- The role of HIV in serious diseases other than AIDSAIDS, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy EraMedical Decision Making, 2003
- Abstention from smoking extends life and compresses morbidity: a population based study of health expectancy among smokers and never smokers in DenmarkTobacco Control, 2001